Amova Asset Management Americas Inc. Reduces Stock Position in Illumina, Inc. $ILMN

Amova Asset Management Americas Inc. cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 18.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 721,532 shares of the life sciences company’s stock after selling 165,333 shares during the period. Illumina comprises 1.3% of Amova Asset Management Americas Inc.’s holdings, making the stock its 25th largest holding. Amova Asset Management Americas Inc.’s holdings in Illumina were worth $88,864,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Elyxium Wealth LLC purchased a new position in Illumina in the fourth quarter worth about $25,000. Creative Capital Management Investments LLC increased its stake in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new stake in Illumina during the fourth quarter valued at approximately $26,000. Laurel Wealth Advisors LLC purchased a new stake in Illumina during the fourth quarter valued at approximately $26,000. Finally, Activest Wealth Management lifted its stake in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 215 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ILMN. TD Cowen reiterated a “hold” rating on shares of Illumina in a report on Wednesday, July 15th. Royal Bank Of Canada initiated coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target for the company. Guggenheim lifted their price objective on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Evercore reiterated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Finally, Canaccord Genuity Group increased their target price on shares of Illumina from $140.00 to $190.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Nine research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $156.88.

Insiders Place Their Bets

In other news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 in the last three months. 2.90% of the stock is owned by company insiders.

Illumina Trading Down 1.1%

Shares of NASDAQ ILMN opened at $184.68 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The business’s 50 day moving average price is $167.28 and its 200-day moving average price is $143.77. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $196.66. The company has a market cap of $27.94 billion, a price-to-earnings ratio of 33.58, a PEG ratio of 3.49 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the business earned $0.97 EPS. Illumina’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 5.22 earnings per share for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.